SNPMiner Trials (Home Page)
Report for Mutation E354Q
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide
The bone tissue of the human adult body is in a constant process of break-down (resorption) and rebuilding (formation), a process called bone remodeling. The extent to which bone remodeling happens varies during the day, especially a decrease in the bone resorption is observed after eating. The overall purpose of this study is to examine the possible role of the hormone Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from cells in the gut after eating, and previous studies have shown an effect of GIP on bone tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in women with a mutation in the GIP receptor, when compared to women with a normal functioning GIP receptor. In the present study humans with a mutation in their GIP receptor is compared to humans with a normal functioning GIP receptor. The study population will be examined during a meal stimulation test, where blood will be sampled regularly. The blood samples will be examined for markers of bone resorption among other markers of bone remodeling, GIP and other gut hormones. The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone resorption. Thus it is expected that the decrease in resorption is less pronounced in the humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP receptor.
NCT02518737 Bone Remodeling Other: Meal Test
CTx is a biomarker of bone resorption.. Inclusion Criteria: - Verified mutation (Glu354Gln) of the GIP-receptor Exclusion Criteria: - Type 2 diabetes - Pregnancy - Previous long-lasting treatment with steroids - On-going steroid treatment (with the exception of inhalation-steroids) - Osteoporosis Inclusion Criteria: - Verified mutation (Glu354Gln) of the GIP-receptor Exclusion Criteria: - Type 2 diabetes - Pregnancy - Previous long-lasting treatment with steroids - On-going steroid treatment (with the exception of inhalation-steroids) - Osteoporosis Bone Remodeling null --- Glu354Gln ---
CTx is a biomarker of bone resorption.. Inclusion Criteria: - Verified mutation (Glu354Gln) of the GIP-receptor Exclusion Criteria: - Type 2 diabetes - Pregnancy - Previous long-lasting treatment with steroids - On-going steroid treatment (with the exception of inhalation-steroids) - Osteoporosis Inclusion Criteria: - Verified mutation (Glu354Gln) of the GIP-receptor Exclusion Criteria: - Type 2 diabetes - Pregnancy - Previous long-lasting treatment with steroids - On-going steroid treatment (with the exception of inhalation-steroids) - Osteoporosis Bone Remodeling null --- Glu354Gln --- --- Glu354Gln ---
Primary Outcomes
Description: CTx is a biomarker of bone resorption.
Measure: CTx Time: 7, 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes after intake of the meal test.